Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
38 hedge funds and large institutions have $76.5M invested in Marinus Pharmaceuticals, Inc in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 10 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more capital invested
Capital invested by funds: $54.3M → $76.5M (+$22.3M)
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$7.08M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.95M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$4.22M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.99M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.02M |
| 2 |
Goldman Sachs
New York
|
-$641K |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$626K |
| 4 |
Morgan Stanley
New York
|
-$499K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$457K |
MRNS Hedge Fund Activity: Q4 2015 in Review
38 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2015, worth a combined $76.5M — up 41% from $54.3M a quarter earlier.
Fund positioning in MRNS was balanced in Q4 2015: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 7 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $7.08M. The largest seller was AWM Investment Company, exiting entirely with an estimated $1.02M sold.
- 38 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $76.5M of Marinus Pharmaceuticals, Inc stock for Q4 2015, up 41% quarter-over-quarter.
- 10 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2015 and 10 closed out, a net change of 0 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2015 was OrbiMed, an estimated $7.08M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2015 was AWM Investment Company, an estimated $1.02M sold.
Based on aggregated 13F filings for Q4 2015.